25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

AKRO (Akero Therapeutics Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Akero Therapeutics Inc together

I guess you are interested in Akero Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Akero Therapeutics Inc’s Financial Insights
  • 📈 Technical Analysis (TA) – Akero Therapeutics Inc’s Price Targets

I'm going to help you getting a better view of Akero Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Akero Therapeutics Inc

I send you an email if I find something interesting about Akero Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Akero Therapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of Akero Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
10.0%

What is your share worth?

Current worth
$13.60
Expected worth in 1 year
$16.58
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
$2.98
Return On Investment
5.8%

For what price can you sell your share?

Current Price per Share
$51.41
Expected price per share
$37.28 - $57.78
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Akero Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
$51.41
Intrinsic Value Per Share
$-42.30 - $-50.02
Total Value Per Share
$-28.70 - $-36.43

2.2. Growth of Akero Therapeutics Inc (5 min.)




Is Akero Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$1b$645.2m$197.3m23.4%

How much money is Akero Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$67.3m-$44.8m-$22.5m-33.5%
Net Profit Margin0.0%-4,857.9%--

How much money comes from the company's main activities?

2.3. Financial Health of Akero Therapeutics Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#60 / 884

Most Revenue
#810 / 884

Most Profit
#824 / 884

Most Efficient
#219 / 884
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Akero Therapeutics Inc?

Welcome investor! Akero Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Akero Therapeutics Inc.

First you should know what it really means to hold a share of Akero Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Akero Therapeutics Inc is $51.41. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Akero Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Akero Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $13.60. Based on the TTM, the Book Value Change Per Share is $0.75 per quarter. Based on the YOY, the Book Value Change Per Share is $1.69 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Akero Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.89-1.7%-0.84-1.6%-0.56-1.1%-0.59-1.1%-0.47-0.9%-0.37-0.7%
Usd Book Value Change Per Share4.198.1%0.751.4%1.693.3%0.981.9%0.611.2%0.450.9%
Usd Dividend Per Share0.000.0%0.000.0%2.114.1%0.701.4%0.420.8%0.280.5%
Usd Total Gains Per Share4.198.1%0.751.4%3.817.4%1.683.3%1.032.0%0.741.4%
Usd Price Per Share40.48-30.11-36.47-33.57-29.80-22.71-
Price to Earnings Ratio-11.41--8.88--18.31--17.63--19.29--17.72-
Price-to-Total Gains Ratio9.67-30.18--25.60-2.37--30.82--41.80-
Price to Book Ratio2.98-2.84-4.70-5.54-7.36-6.58-
Price-to-Total Gains Ratio9.67-30.18--25.60-2.37--30.82--41.80-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share51.41
Number of shares19
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.42
Usd Book Value Change Per Share0.750.61
Usd Total Gains Per Share0.751.03
Gains per Quarter (19 shares)14.1619.54
Gains per Year (19 shares)56.6378.16
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
105747324668
201131046492146
3017016196138224
40227218129184302
50283275161230380
60340332193276458
70396389225322536
80453446257368614
90510503289414692
100566560321460770

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.030.00.00.0%0.030.00.00.0%
Book Value Change Per Share2.02.00.050.0%6.06.00.050.0%7.013.00.035.0%11.017.02.036.7%11.017.02.036.7%
Dividend per Share0.00.04.00.0%3.00.09.025.0%3.00.017.015.0%3.00.027.010.0%3.00.027.010.0%
Total Gains per Share2.02.00.050.0%7.05.00.058.3%8.012.00.040.0%12.016.02.040.0%12.016.02.040.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Akero Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--4.1860.745+462%1.693+147%0.980+327%0.606+591%0.453+824%
Book Value Per Share--13.59610.570+29%8.095+68%7.397+84%5.460+149%3.882+250%
Current Ratio--16.80419.582-14%27.353-39%20.755-19%18.488-9%17.665-5%
Debt To Asset Ratio--0.0620.082-24%0.076-18%0.094-34%0.091-32%0.162-61%
Debt To Equity Ratio--0.0660.090-26%0.082-19%0.106-37%0.102-35%0.135-51%
Dividend Per Share----0%2.113-100%0.705-100%0.423-100%0.282-100%
Enterprise Value--3841264448.0003053706980.000+26%3516633622.000+9%3189276072.000+20%2761372300.800+39%2607079362.833+47%
Eps---0.887-0.845-5%-0.562-37%-0.586-34%-0.473-47%-0.374-58%
Ev To Ebitda Ratio---11.873-11.073-7%-22.380+88%-20.721+75%-21.966+85%-24.598+107%
Free Cash Flow Per Share---0.849-0.824-3%-0.489-42%-0.536-37%-0.423-50%-0.304-64%
Free Cash Flow To Equity Per Share--4.1130.664+519%1.722+139%0.980+320%0.614+570%0.493+734%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---50.021----------
Intrinsic Value_10Y_min---42.297----------
Intrinsic Value_1Y_max---2.563----------
Intrinsic Value_1Y_min---2.516----------
Intrinsic Value_3Y_max---9.567----------
Intrinsic Value_3Y_min---9.096----------
Intrinsic Value_5Y_max---18.823----------
Intrinsic Value_5Y_min---17.310----------
Market Cap4098281816.000+21%3226968448.0002400496230.000+34%2907300872.000+11%2676451988.667+21%2375225750.800+36%1810134256.933+78%
Net Profit Margin----0%-48.5790%-16.1930%-9.7160%-6.4770%
Operating Margin----0%-47.7900%-15.9300%-9.5580%-6.3720%
Operating Ratio----0%54.466-100%18.155-100%10.893-100%7.262-100%
Pb Ratio3.781+21%2.9772.844+5%4.702-37%5.541-46%7.361-60%6.585-55%
Pe Ratio-14.487-27%-11.407-8.885-22%-18.306+60%-17.634+55%-19.290+69%-17.721+55%
Price Per Share51.410+21%40.48030.113+34%36.470+11%33.574+21%29.796+36%22.707+78%
Price To Free Cash Flow Ratio-15.142-27%-11.923-9.111-24%-21.433+80%-19.430+63%-21.846+83%-20.608+73%
Price To Total Gains Ratio12.280+21%9.66930.182-68%-25.602+365%2.368+308%-30.824+419%-41.804+532%
Quick Ratio--27.96230.359-8%38.136-27%28.760-3%24.784+13%22.352+25%
Return On Assets---0.061-0.075+22%-0.066+7%-0.077+26%-0.093+52%-0.659+978%
Return On Equity---0.065-0.082+25%-0.071+9%-0.086+32%-0.103+58%-0.936+1334%
Total Gains Per Share--4.1860.745+462%3.806+10%1.684+149%1.028+307%0.735+470%
Usd Book Value--1083846000.000842587500.000+29%645282750.000+68%589689000.000+84%435276300.000+149%309427833.333+250%
Usd Book Value Change Per Share--4.1860.745+462%1.693+147%0.980+327%0.606+591%0.453+824%
Usd Book Value Per Share--13.59610.570+29%8.095+68%7.397+84%5.460+149%3.882+250%
Usd Dividend Per Share----0%2.113-100%0.705-100%0.423-100%0.282-100%
Usd Enterprise Value--3841264448.0003053706980.000+26%3516633622.000+9%3189276072.000+20%2761372300.800+39%2607079362.833+47%
Usd Eps---0.887-0.845-5%-0.562-37%-0.586-34%-0.473-47%-0.374-58%
Usd Free Cash Flow---67664000.000-65657750.000-3%-38968750.000-42%-42731583.333-37%-33748550.000-50%-24253145.433-64%
Usd Free Cash Flow Per Share---0.849-0.824-3%-0.489-42%-0.536-37%-0.423-50%-0.304-64%
Usd Free Cash Flow To Equity Per Share--4.1130.664+519%1.722+139%0.980+320%0.614+570%0.493+734%
Usd Market Cap4098281816.000+21%3226968448.0002400496230.000+34%2907300872.000+11%2676451988.667+21%2375225750.800+36%1810134256.933+78%
Usd Price Per Share51.410+21%40.48030.113+34%36.470+11%33.574+21%29.796+36%22.707+78%
Usd Profit---70725000.000-67360250.000-5%-44818000.000-37%-46246666.667-35%-37453250.000-47%-29581542.400-58%
Usd Revenue----0%71000.000-100%23666.667-100%14200.000-100%9466.667-100%
Usd Total Gains Per Share--4.1860.745+462%3.806+10%1.684+149%1.028+307%0.735+470%
 EOD+6 -2MRQTTM+20 -13YOY+22 -153Y+22 -155Y+23 -1410Y+23 -14

3.3 Fundamental Score

Let's check the fundamental score of Akero Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-14.487
Price to Book Ratio (EOD)Between0-13.781
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than127.962
Current Ratio (MRQ)Greater than116.804
Debt to Asset Ratio (MRQ)Less than10.062
Debt to Equity Ratio (MRQ)Less than10.066
Return on Equity (MRQ)Greater than0.15-0.065
Return on Assets (MRQ)Greater than0.05-0.061
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Akero Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.907
Ma 20Greater thanMa 5054.233
Ma 50Greater thanMa 10047.656
Ma 100Greater thanMa 20045.970
OpenGreater thanClose52.880
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Akero Therapeutics Inc

Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Fundamental data was last updated by Penke on 2025-06-18 22:46:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Akero Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Akero Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Akero Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-4,857.9%+4,857.9%
TTM-5Y-971.6%+971.6%
5Y-971.6%10Y-647.7%-323.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--92.7%+92.7%
TTM--141.4%+141.4%
YOY-4,857.9%-186.1%-4,671.8%
3Y-1,619.3%-248.3%-1,371.0%
5Y-971.6%-338.6%-633.0%
10Y-647.7%-488.9%-158.8%
4.3.1.2. Return on Assets

Shows how efficient Akero Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Akero Therapeutics Inc to the Biotechnology industry mean.
  • -6.1% Return on Assets means that Akero Therapeutics Inc generated $-0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Akero Therapeutics Inc:

  • The MRQ is -6.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -7.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.1%TTM-7.5%+1.4%
TTM-7.5%YOY-6.6%-0.9%
TTM-7.5%5Y-9.3%+1.8%
5Y-9.3%10Y-65.9%+56.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.1%-11.5%+5.4%
TTM-7.5%-11.6%+4.1%
YOY-6.6%-11.4%+4.8%
3Y-7.7%-11.8%+4.1%
5Y-9.3%-12.1%+2.8%
10Y-65.9%-13.8%-52.1%
4.3.1.3. Return on Equity

Shows how efficient Akero Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Akero Therapeutics Inc to the Biotechnology industry mean.
  • -6.5% Return on Equity means Akero Therapeutics Inc generated $-0.07 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Akero Therapeutics Inc:

  • The MRQ is -6.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -8.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.5%TTM-8.2%+1.7%
TTM-8.2%YOY-7.1%-1.1%
TTM-8.2%5Y-10.3%+2.2%
5Y-10.3%10Y-93.6%+83.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.5%-13.6%+7.1%
TTM-8.2%-14.9%+6.7%
YOY-7.1%-14.4%+7.3%
3Y-8.6%-17.0%+8.4%
5Y-10.3%-17.9%+7.6%
10Y-93.6%-20.1%-73.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Akero Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Akero Therapeutics Inc is operating .

  • Measures how much profit Akero Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Akero Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Akero Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-4,779.0%+4,779.0%
TTM-5Y-955.8%+955.8%
5Y-955.8%10Y-637.2%-318.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--229.2%+229.2%
TTM--250.3%+250.3%
YOY-4,779.0%-205.1%-4,573.9%
3Y-1,593.0%-220.2%-1,372.8%
5Y-955.8%-342.6%-613.2%
10Y-637.2%-475.5%-161.7%
4.3.2.2. Operating Ratio

Measures how efficient Akero Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Akero Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY54.466-54.466
TTM-5Y10.893-10.893
5Y10.89310Y7.262+3.631
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.110-2.110
TTM-2.704-2.704
YOY54.4663.063+51.403
3Y18.1553.576+14.579
5Y10.8934.713+6.180
10Y7.2626.512+0.750
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Akero Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Akero Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 16.80 means the company has $16.80 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Akero Therapeutics Inc:

  • The MRQ is 16.804. The company is very able to pay all its short-term debts. +2
  • The TTM is 19.582. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ16.804TTM19.582-2.778
TTM19.582YOY27.353-7.771
TTM19.5825Y18.488+1.094
5Y18.48810Y17.665+0.823
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ16.8043.661+13.143
TTM19.5823.786+15.796
YOY27.3534.121+23.232
3Y20.7554.680+16.075
5Y18.4885.765+12.723
10Y17.6656.150+11.515
4.4.3.2. Quick Ratio

Measures if Akero Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Akero Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 27.96 means the company can pay off $27.96 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Akero Therapeutics Inc:

  • The MRQ is 27.962. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 30.359. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ27.962TTM30.359-2.398
TTM30.359YOY38.136-7.776
TTM30.3595Y24.784+5.576
5Y24.78410Y22.352+2.431
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ27.9622.826+25.136
TTM30.3593.128+27.231
YOY38.1363.782+34.354
3Y28.7604.304+24.456
5Y24.7845.703+19.081
10Y22.3526.454+15.898
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Akero Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Akero Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Akero Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.06 means that Akero Therapeutics Inc assets are financed with 6.2% credit (debt) and the remaining percentage (100% - 6.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Akero Therapeutics Inc:

  • The MRQ is 0.062. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.082. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.062TTM0.082-0.020
TTM0.082YOY0.076+0.006
TTM0.0825Y0.091-0.009
5Y0.09110Y0.162-0.070
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0620.324-0.262
TTM0.0820.347-0.265
YOY0.0760.327-0.251
3Y0.0940.339-0.245
5Y0.0910.349-0.258
10Y0.1620.382-0.220
4.5.4.2. Debt to Equity Ratio

Measures if Akero Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Akero Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 6.6% means that company has $0.07 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Akero Therapeutics Inc:

  • The MRQ is 0.066. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.090. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.066TTM0.090-0.023
TTM0.090YOY0.082+0.008
TTM0.0905Y0.102-0.013
5Y0.10210Y0.135-0.032
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0660.383-0.317
TTM0.0900.436-0.346
YOY0.0820.410-0.328
3Y0.1060.446-0.340
5Y0.1020.460-0.358
10Y0.1350.509-0.374
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Akero Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Akero Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -11.41 means the investor is paying $-11.41 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Akero Therapeutics Inc:

  • The EOD is -14.487. Based on the earnings, the company is expensive. -2
  • The MRQ is -11.407. Based on the earnings, the company is expensive. -2
  • The TTM is -8.885. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-14.487MRQ-11.407-3.080
MRQ-11.407TTM-8.885-2.522
TTM-8.885YOY-18.306+9.421
TTM-8.8855Y-19.290+10.405
5Y-19.29010Y-17.721-1.569
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-14.487-2.197-12.290
MRQ-11.407-2.027-9.380
TTM-8.885-2.527-6.358
YOY-18.306-3.733-14.573
3Y-17.634-3.717-13.917
5Y-19.290-6.036-13.254
10Y-17.721-6.649-11.072
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Akero Therapeutics Inc:

  • The EOD is -15.142. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -11.923. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -9.111. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-15.142MRQ-11.923-3.219
MRQ-11.923TTM-9.111-2.812
TTM-9.111YOY-21.433+12.322
TTM-9.1115Y-21.846+12.735
5Y-21.84610Y-20.608-1.237
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-15.142-3.007-12.135
MRQ-11.923-2.704-9.219
TTM-9.111-3.627-5.484
YOY-21.433-4.334-17.099
3Y-19.430-5.070-14.360
5Y-21.846-8.532-13.314
10Y-20.608-9.305-11.303
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Akero Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.98 means the investor is paying $2.98 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Akero Therapeutics Inc:

  • The EOD is 3.781. Based on the equity, the company is fair priced.
  • The MRQ is 2.977. Based on the equity, the company is underpriced. +1
  • The TTM is 2.844. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.781MRQ2.977+0.804
MRQ2.977TTM2.844+0.134
TTM2.844YOY4.702-1.859
TTM2.8445Y7.361-4.517
5Y7.36110Y6.585+0.777
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.7811.921+1.860
MRQ2.9771.843+1.134
TTM2.8442.113+0.731
YOY4.7022.467+2.235
3Y5.5412.541+3.000
5Y7.3613.666+3.695
10Y6.5854.311+2.274
4.6.2. Total Gains per Share

2.4. Latest News of Akero Therapeutics Inc

Does Akero Therapeutics Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Akero Therapeutics Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-06-21
03:29
Akero therapeutics CSO Rolph sells $61,914 in sharesRead
2025-06-21
03:26
Akero Therapeutics SVP Lamy sells $47k in sharesRead
2025-06-21
03:24
Akero Therapeutics (AKRO) CEO Andrew Cheng sells $363k in stockRead
2025-06-21
03:23
Akero Therapeutics CTO Gangloff sells $46,504 in stockRead
2025-06-21
03:12
Akero Therapeutics (AKRO) CFO White sells $89k in stockRead
2025-06-21
03:10
Akero therapeutics chief development officer Yale sells $89k in stockRead
2025-06-13
18:29
Jefferies sees promising M&A targets in biotech sector amid stabilizing marketRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Akero Therapeutics Inc.

4.8.1. Institutions holding Akero Therapeutics Inc

Institutions are holding 109.291% of the shares of Akero Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31RTW INVESTMENTS, LLC9.31154.593474193405595178.1564
2025-03-31HHG PLC8.87140.16557068648103440917.1423
2025-03-31BlackRock Inc7.85030.005362550243308415.5846
2025-03-31Wellington Management Company LLP7.45020.04625936240-1440721-19.53
2025-03-31General Atlantic Llc6.56887.1121523398900
2025-03-31T. Rowe Price Associates, Inc.6.04560.024481709149511911.4559
2025-03-31Vanguard Group Inc5.30960.0031423064452623314.2056
2025-03-31Deep Track Capital, LP4.0294.20832102701720270115.4544
2025-03-31State Street Corp3.1310.004224947431587996.7981
2025-03-31Citadel Advisors Llc2.39630.0147190933055443740.9211
2024-12-31AllianceBernstein L.P.2.30840.01741839281-177807-8.815
2025-03-31Geode Capital Management, LLC2.19530.0056174919418956312.1543
2025-03-31Marshall Wace Asset Management Ltd2.01790.082616078421332768484.5125
2025-03-31Alkeon Capital Management, LLC1.94650.13081550934-210334-11.9422
2025-03-31Bellevue Group AG1.56961.1344125066612506660
2025-03-31Logos Global Management LP1.5068.6351120000040000050
2025-03-31SG Americas Securities, LLC1.45060.1535115578755779493.2777
2025-03-31FMR Inc1.26650.002610091279704032505.9472
2025-03-31Redmile Group, LLC1.17883.5938939277-295932-23.9581
2025-03-31Morgan Stanley - Brokerage Accounts1.00760.002380285433131970.2639
Total 77.410929.934661680281+8287344+13.4%

4.9.2. Funds holding Akero Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Vanguard Health Care Inv4.59030.38013657502-743666-16.897
2025-04-30Vanguard Total Stock Mkt Idx Inv2.88920.0061230207479810.3479
2025-05-31iShares Russell 2000 ETF2.3460.1507186924600
2025-03-31US Small-Cap Growth II Equity Comp2.27230.45511810534295031.6565
2025-03-31T. Rowe Price New Horizons2.27230.45511810534-24484-1.3343
2025-03-31Janus Henderson Global Life Sciences1.94961.33691553410-82264-5.0294
2025-03-31Janus Henderson Global Life Sciences D1.94961.33821553410-3776-0.2425
2025-03-31Janus Global Life Science AUSD1.57871.33211257919-43354-3.3317
2025-04-30Janus Henderson Glb Life Scn I2 USD1.56191.51631244512-13407-1.0658
2025-03-31T. Rowe Price Health Sciences1.56020.40821243181-18774-1.4877
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr1.35470.0483107941539470.367
2024-12-31ACAP Strategic A1.07080.2758853237-733582-46.2297
2025-05-31SPDR® S&P Biotech ETF1.06980.90285243050400.5948
2025-03-31Fidelity Small Cap Index0.93470.12477447857237510.7635
2025-05-31iShares Russell 2000 Value ETF0.7060.260256254300
2025-03-31T. Rowe Price New Horizons Tr-A0.64570.46155145155089810.9785
2025-05-31State St Russell Sm/Mid Cp® Indx SL Cl I0.54310.052243270900
2025-03-31T. Rowe Price Integrated US SmCapGrEq0.52150.2235415520-415520-50
2025-03-31T. Rowe Price Integrated US Sm Gr Eq0.52150.223541552000
2025-03-31Lord Abbett Developing Growth A0.4940.874393632-206705-34.4315
Total 30.831910.824524566628-2115788-8.6%

5.3. Insider Transactions

Insiders are holding 1.389% of the shares of Akero Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-06-10Catriona YaleSELL280354
2025-06-10Jonathan YoungSELL249353.99
2025-06-10Patrick LamySELL91954
2025-06-10Timothy RolphSELL235854
2025-06-10William Richard WhiteSELL280453.99
2025-06-10Andrew ChengSELL3783754.05
2025-06-06Timothy RolphSELL2500055.04
2025-06-05Timothy RolphSELL1250053.49
2025-06-02Patrick LamySELL400050.31
2025-05-22Patrick LamySELL400050
2025-05-15Catriona YaleSELL1000039.3
2025-05-12Andrew ChengSELL3000041.48
2025-05-07Patrick LamySELL800042.49
2025-05-06Timothy RolphSELL1250043.43
2025-04-24Timothy RolphSELL625041.03
2025-04-15Catriona YaleSELL907337.91
2025-04-10Andrew ChengSELL3000035.23
2025-04-07Timothy RolphSELL625035.88
2025-03-27G. Walmsley GrahamBUY5000043.55
2025-03-25G. Walmsley GrahamBUY9130944.75
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,155,843
Total Liabilities71,997
Total Stockholder Equity1,083,846
 As reported
Total Liabilities 71,997
Total Stockholder Equity+ 1,083,846
Total Assets = 1,155,843

Assets

Total Assets1,155,843
Total Current Assets713,151
Long-term Assets442,692
Total Current Assets
Cash And Cash Equivalents 185,922
Short-term Investments 500,371
Other Current Assets 26,858
Total Current Assets  (as reported)713,151
Total Current Assets  (calculated)713,151
+/-0
Long-term Assets
Property Plant Equipment 689
Long Term Investments 442,003
Long-term Assets  (as reported)442,692
Long-term Assets  (calculated)442,692
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities42,439
Long-term Liabilities29,558
Total Stockholder Equity1,083,846
Total Current Liabilities
Short-term Debt 6,664
Short Long Term Debt 6,664
Accounts payable 10,831
Other Current Liabilities 14,113
Total Current Liabilities  (as reported)42,439
Total Current Liabilities  (calculated)38,272
+/- 4,167
Long-term Liabilities
Long term Debt 28,811
Capital Lease Obligations 1,096
Long-term Liabilities  (as reported)29,558
Long-term Liabilities  (calculated)29,907
+/- 349
Total Stockholder Equity
Common Stock8
Retained Earnings -896,881
Accumulated Other Comprehensive Income 1,085
Other Stockholders Equity 1,979,634
Total Stockholder Equity (as reported)1,083,846
Total Stockholder Equity (calculated)1,083,846
+/-0
Other
Capital Stock8
Cash and Short Term Investments 686,293
Common Stock Shares Outstanding 78,657
Liabilities and Stockholders Equity 1,155,843
Net Debt -178,807
Net Invested Capital 1,119,321
Net Working Capital 670,712
Property Plant and Equipment Gross 689
Short Long Term Debt Total 7,115



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
> Total Assets 
658
0
0
8,455
77,151
72,066
163,168
150,143
138,118
126,621
114,058
300,036
273,339
257,623
238,009
223,533
195,548
169,887
185,675
379,408
356,570
348,818
663,806
635,331
580,271
912,243
865,043
817,547
825,886
1,155,843
1,155,843825,886817,547865,043912,243580,271635,331663,806348,818356,570379,408185,675169,887195,548223,533238,009257,623273,339300,036114,058126,621138,118150,143163,16872,06677,1518,45500658
   > Total Current Assets 
638
598
0
8,435
77,131
70,699
163,108
150,073
138,049
126,218
113,193
298,033
271,345
255,776
236,222
221,807
193,582
167,934
184,147
377,946
355,173
347,489
643,203
575,979
559,962
911,280
776,010
746,888
770,380
713,151
713,151770,380746,888776,010911,280559,962575,979643,203347,489355,173377,946184,147167,934193,582221,807236,222255,776271,345298,033113,193126,218138,049150,073163,10870,69977,1318,4350598638
       Cash And Cash Equivalents 
598
-598
0
7,832
75,975
69,796
162,654
147,835
136,400
47,245
63,247
192,679
187,242
187,960
157,538
164,935
150,483
150,489
177,727
374,003
249,773
257,884
444,156
269,546
234,207
623,854
310,355
316,065
340,238
185,922
185,922340,238316,065310,355623,854234,207269,546444,156257,884249,773374,003177,727150,489150,483164,935157,538187,960187,242192,67963,24747,245136,400147,835162,65469,79675,9757,8320-598598
       Short-term Investments 
0
1,196
0
0
0
0
0
0
71,612
78,040
39,586
99,191
81,145
62,024
72,490
50,146
37,775
14,887
2,998
0
101,676
85,338
195,288
285,186
315,803
279,811
449,839
401,182
402,840
500,371
500,371402,840401,182449,839279,811315,803285,186195,28885,338101,67602,99814,88737,77550,14672,49062,02481,14599,19139,58678,04071,6120000001,1960
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
201
115
115
114
417
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000417114115115201000000000000
       Other Current Assets 
40
0
0
603
2,312
1,806
908
4,476
3,298
1,866
20,720
12,326
5,916
11,584
12,388
13,452
10,648
5,116
6,844
7,886
7,448
4,267
3,759
21,247
9,952
7,615
15,816
29,641
27,302
26,858
26,85827,30229,64115,8167,6159,95221,2473,7594,2677,4487,8866,8445,11610,64813,45212,38811,5845,91612,32620,7201,8663,2984,4769081,8062,3126030040
   > Long-term Assets 
20
-598
0
20
20
1,367
60
70
69
403
865
2,003
1,994
1,847
1,787
1,726
1,966
1,953
1,528
1,462
1,397
1,329
20,603
59,352
20,309
963
89,033
70,659
55,506
442,692
442,69255,50670,65989,03396320,30959,35220,6031,3291,3971,4621,5281,9531,9661,7261,7871,8471,9942,0038654036970601,36720200-59820
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
226
0
1,847
1,793
1,732
1,672
1,612
1,549
1,485
1,420
1,354
1,289
1,221
1,152
1,088
1,026
963
900
835
755
689
6897558359009631,0261,0881,1521,2211,2891,3541,4201,4851,5491,6121,6721,7321,7931,8470226000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
19,451
58,264
19,283
0
88,133
69,824
54,751
442,003
442,00354,75169,82488,133019,28358,26419,4510000000000000000000000
       Other Assets 
20
0
0
0
20
1,367
60
70
69
177
865
156
201
115
115
1,726
417
468
0
108
108
0
0
0
0
0
0
0
0
0
00000000010810804684171,7261151152011568651776970601,3672000020
> Total Liabilities 
222
0
0
1,019
127,070
2,404
4,779
6,759
9,392
8,298
10,395
13,578
14,627
11,603
17,876
24,905
26,439
23,352
37,303
35,900
30,008
42,473
47,369
52,196
44,965
65,990
66,976
79,222
75,774
71,997
71,99775,77479,22266,97665,99044,96552,19647,36942,47330,00835,90037,30323,35226,43924,90517,87611,60314,62713,57810,3958,2989,3926,7594,7792,404127,0701,01900222
   > Total Current Liabilities 
222
0
0
1,019
2,342
2,404
4,740
6,725
9,369
8,286
10,393
12,014
13,111
10,136
16,459
23,540
25,128
22,097
26,697
25,243
19,083
16,678
21,602
28,447
19,128
30,259
31,174
43,291
39,754
42,439
42,43939,75443,29131,17430,25919,12828,44721,60216,67819,08325,24326,69722,09725,12823,54016,45910,13613,11112,01410,3938,2869,3696,7254,7402,4042,3421,01900222
       Short-term Debt 
0
0
0
0
0
0
0
0
85
230
0
303
294
337
227
199
205
212
255
303
325
410
493
2,581
522
640
629
631
631
6,664
6,6646316316296405222,58149341032530325521220519922733729430302308500000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,076
0
0
0
0
0
6,664
6,664000002,07600000000000000000000000
       Accounts payable 
60
0
0
519
1,373
952
3,248
93
947
1,535
2,536
4,636
3,428
4,605
2,307
6,784
6,706
4,450
6,877
6,010
7,968
7,080
10,121
11,454
7,038
13,783
14,568
25,223
9,027
10,831
10,8319,02725,22314,56813,7837,03811,45410,1217,0807,9686,0106,8774,4506,7066,7842,3074,6053,4284,6362,5361,535947933,2489521,3735190060
       Other Current Liabilities 
162
0
0
500
969
1,452
1,492
6,632
8,337
6,521
7,857
7,075
9,389
5,194
13,925
16,557
18,217
17,435
19,565
18,930
10,790
9,188
10,988
14,412
11,568
15,836
15,977
17,437
30,096
14,113
14,11330,09617,43715,97715,83611,56814,41210,9889,18810,79018,93019,56517,43518,21716,55713,9255,1949,3897,0757,8576,5218,3376,6321,4921,45296950000162
   > Long-term Liabilities 
0
0
0
0
124,728
952
39
34
23
12
2
1,564
1,516
1,467
1,417
1,365
1,311
1,255
10,606
10,657
10,925
25,795
25,767
23,749
25,837
35,731
35,802
35,931
36,020
29,558
29,55836,02035,93135,80235,73125,83723,74925,76725,79510,92510,65710,6061,2551,3111,3651,4171,4671,5161,564212233439952124,7280000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,366
9,447
9,541
24,616
0
0
0
0
0
0
0
0
0000000024,6169,5419,4479,366000000000000000000
       Other Liabilities 
0
0
0
0
0
0
39
34
23
12
2
0
0
0
0
1,365
0
0
41
70
305
0
85
0
0
0
0
0
0
0
00000008503057041001,3650000212233439000000
       Deferred Long Term Liability 
0
0
0
0
0
1,327
0
0
0
0
0
0
46
0
0
0
0
0
41
70
305
162
0
0
0
0
0
0
0
0
00000000162305704100000460000001,32700000
> Total Stockholder Equity
436
436
0
4,765
-49,919
69,662
158,389
143,384
128,726
118,323
103,663
286,458
258,712
246,020
220,133
198,628
169,109
146,535
148,372
343,508
326,562
306,345
616,437
583,135
535,306
846,253
798,067
738,325
750,112
1,083,846
1,083,846750,112738,325798,067846,253535,306583,135616,437306,345326,562343,508148,372146,535169,109198,628220,133246,020258,712286,458103,663118,323128,726143,384158,38969,662-49,9194,7650436436
   Common Stock
0
0
0
0
0
2
3
3
3
3
3
4
4
4
4
4
4
4
4
5
5
5
6
6
6
7
7
7
7
8
877776665554444444433333200000
   Retained Earnings Total Equity00000000-448,168-422,337-399,278-363,736-336,333-310,304-277,880-253,550-224,617-209,527000000000000
   Accumulated Other Comprehensive Income 
0
-4,564
0
0
0
0
-163,168
-150,143
-6
45
90
16
-3
-2
-9
-17
-27
-30
-3
0
37
21
-251
-506
270
-79
-261
2,103
948
1,085
1,0859482,103-261-79270-506-25121370-3-30-27-17-9-2-3169045-6-150,143-163,1680000-4,5640
   Capital Surplus 
0
0
0
0
36,646
36,861
257,541
258,090
259,049
260,481
0
0
468,238
470,635
473,688
476,521
479,436
482,894
512,107
742,781
748,857
754,487
0
0
0
0
0
0
0
0
00000000754,487748,857742,781512,107482,894479,436476,521473,688470,635468,23800260,481259,049258,090257,54136,86136,6460000
   Treasury Stock000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
-88,082
36,861
420,709
408,233
259,049
260,481
261,983
466,254
468,238
470,635
473,688
476,521
479,436
482,894
512,107
742,781
748,857
754,487
1,095,933
1,102,545
1,109,126
1,473,765
1,481,748
1,492,347
1,575,313
1,979,634
1,979,6341,575,3131,492,3471,481,7481,473,7651,109,1261,102,5451,095,933754,487748,857742,781512,107482,894479,436476,521473,688470,635468,238466,254261,983260,481259,049408,233420,70936,861-88,0820000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-285,423
Operating Income-285,423-285,423
 
Operating Expense (+$)
Research Development247,497
Selling General Administrative37,926
Selling And Marketing Expenses0
Operating Expense285,423285,423
 
Net Interest Income (+$)
Interest Income38,031
Interest Expense-4,668
Other Finance Cost-0
Net Interest Income33,363
 
Pretax Income (+$)
Operating Income-285,423
Net Interest Income33,363
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-252,060-318,786
EBIT - interestExpense = -261,396
-252,060
-247,392
Interest Expense4,668
Earnings Before Interest and Taxes (EBIT)-256,728-247,392
Earnings Before Interest and Taxes (EBITDA)-285,423
 
After tax Income (+$)
Income Before Tax-252,060
Tax Provision-0
Net Income From Continuing Ops-252,060-252,060
Net Income-252,060
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net33,363-33,363
 

Technical Analysis of Akero Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Akero Therapeutics Inc. The general trend of Akero Therapeutics Inc is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Akero Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Akero Therapeutics Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Akero Therapeutics Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 51.42 < 57.07 < 57.78.

The bearish price targets are: 52.74 > 44.94 > 37.28.

Know someone who trades $AKRO? Share this with them.👇

Akero Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Akero Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Akero Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Akero Therapeutics Inc. The current macd is 1.76877198.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Akero Therapeutics Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Akero Therapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Akero Therapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Akero Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAkero Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Akero Therapeutics Inc. The current adx is 26.12.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Akero Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Akero Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Akero Therapeutics Inc. The current sar is 57.35.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Akero Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Akero Therapeutics Inc. The current rsi is 47.91. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Akero Therapeutics Inc Daily Relative Strength Index (RSI) ChartAkero Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Akero Therapeutics Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Akero Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Akero Therapeutics Inc Daily Stochastic Oscillator ChartAkero Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Akero Therapeutics Inc. The current cci is -149.8455717.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Akero Therapeutics Inc Daily Commodity Channel Index (CCI) ChartAkero Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Akero Therapeutics Inc. The current cmo is -22.92212214.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Akero Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAkero Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Akero Therapeutics Inc. The current willr is -95.34510433.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Akero Therapeutics Inc Daily Williams %R ChartAkero Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Akero Therapeutics Inc.

Akero Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Akero Therapeutics Inc. The current atr is 2.59433895.

Akero Therapeutics Inc Daily Average True Range (ATR) ChartAkero Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Akero Therapeutics Inc. The current obv is 8,787,346.

Akero Therapeutics Inc Daily On-Balance Volume (OBV) ChartAkero Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Akero Therapeutics Inc. The current mfi is 60.51.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Akero Therapeutics Inc Daily Money Flow Index (MFI) ChartAkero Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Akero Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-02-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-02-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-24STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-27MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-07BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-24CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-04-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-04-29MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-04-30BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-02MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-10MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-06-13STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.

6.3. Candlestick Patterns

Akero Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Akero Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.907
Ma 20Greater thanMa 5054.233
Ma 50Greater thanMa 10047.656
Ma 100Greater thanMa 20045.970
OpenGreater thanClose52.880
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Akero Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Akero Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Akero Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Akero Therapeutics Inc

I send you an email if I find something interesting about Akero Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Akero Therapeutics Inc.

Receive notifications about Akero Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.